Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol

被引：0
|
作者：
Ditte Hansen
Lisbet Brandi
Knud Rasmussen
机构：
[1] Roskilde Hospital,Medical Department
[2] University of Copenhagen,Department of Surgery and Internal Medicine
来源：
BMC Nephrology | / 10卷
关键词：
Chronic Kidney Disease; Hypercalcemia; Vascular Calcification; Secondary Hyperparathyroidism; Alfacalcidol;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol
    Hansen, Ditte
    Brandi, Lisbet
    Rasmussen, Knud
    BMC NEPHROLOGY, 2009, 10
  • [2] Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients
    Kiattisunthorn, Kraiwiporn
    Wutyam, Kittikarn
    Indranoi, Artit
    Vasuvattakul, Somkiat
    NEPHROLOGY, 2011, 16 (03) : 277 - 284
  • [3] TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN MAINTANENCE HEMODIALYSIS PATIENTS: A RANDOMISED CLINICAL TRIAL COMPARING PARICALCITOL, CALCITRIOL AND SINACALCET
    Sezer, Siren
    Tutal, Emre
    Bal, Zeynep
    Ozelsancak, Ruya
    Demirci, Bahar Gurlek
    Torun, Dilek
    Acar, F. Nurhan Ozdemir
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 509 - 510
  • [4] Health-Economic Comparison of Paricalcitol, Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism during Haemodialysis
    Hubertus Rosery
    Rito Bergemann
    Steven E. Marx
    Axel Boehnke
    Joel Melnick
    Raimund Sterz
    Laura Williams
    Clinical Drug Investigation, 2006, 26 : 629 - 638
  • [5] Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis
    Rosery, Hubertus
    Bergemann, Rito
    Marx, Steven E.
    Boehnke, Axel
    Melnick, Joel
    Sterz, Raimund
    Williams, Laura
    CLINICAL DRUG INVESTIGATION, 2006, 26 (11) : 629 - 638
  • [6] No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial
    Hansen, Ditte
    Rasmussen, Knud
    Danielsen, Henning
    Meyer-Hofmann, Helmut
    Bacevicius, Egidijus
    Lauridsen, Thomas G.
    Madsen, Jens K.
    Tougaard, Birgitte G.
    Marckmann, Peter
    Thye-Roenn, Peter
    Nielsen, Jorgen E.
    Kreiner, Svend
    Brandi, Lisbet
    KIDNEY INTERNATIONAL, 2011, 80 (08) : 841 - 850
  • [7] Health-Economic Comparison of Paricalcitol, Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism during Haemodialysis
    Roman Fiedler
    Clinical Drug Investigation, 2007, 27 : 865 - 866
  • [8] Health-economic comparison of paricalcitol, calcitriol and Alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis
    Fiedler, Roman
    CLINICAL DRUG INVESTIGATION, 2007, 27 (12) : 865 - 866
  • [9] A Randomised Clinical Study of Alfacalcidol and Paricalcitol
    Hansen, Ditte
    DANISH MEDICAL JOURNAL, 2012, 59 (02):
  • [10] Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol
    Hansen, Ditte
    Rasmussen, Knud
    Pedersen, Susanne M.
    Rasmussen, Lars M.
    Brandi, Lisbet
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (06) : 2263 - 2269
12345